CEO: Guni Goolab
CFO: Neil MacGregor
Directors: Legal and Compliance: Louendrie Pillay,
Sales and Marketing – Specialist Care: Christo Kruger,
Sales and Marketing – Primary Care:
Karl Friberg
Medical, Clinical and Regulatory: Khanyi Mzolo
Human Resources: Katie Schaefer
Physical address: 5 Leeuwkop Road, Sunninghill 2157
Postal address: Private Bag X30, Sunninghill 2157
Telephone: +27 (0)11 797 6000
Fax: +27 (0)11 797 6001



AstraZeneca is a global, innovation-driven and integrated biopharmaceutical corporation. Its mission is to make a meaningful difference to patients through great medicines that bring benefits to their health, and add value to stakeholders and society. AstraZeneca manufactures and markets prescription medicines for six important areas of healthcare, which include some of the world’s most serious illnesses.

For patients and physicians, it provides medicines for some of the world’s most serious diseases. For the people who pay for healthcare, it works to make sure that the medicines offer real value for money. For its employees, it provides a culture in which they can feel appreciated, energised and rewarded for their contribution. For its shareholders, it aims to deliver value through its continued focus on innovation and running its business efficiently.

For the wider community, it wants to be valued for the contribution its medicines can make to society and trusted for the way in which it does business.

It works closely with all stakeholders to understand their challenges and how it can combine its skills and resources to achieve a common goal of improved health.

Because health connects us all.


Year founded: Merging of Astra Pharmaceuticals (Pty) Ltd and Zeneca Pharmaceuticals (Pty) Ltd at the end of 1999
Employees: Over 61 000 employees (46% in Europe, 24% in the North America, 7% in Latin America and 24% in Asia, Africa and Australasia); 9 300 employees at 23 supply and manufacturing sites in 16 countries, 250 in SA of which 116 is field force
Branches: Johannesburg (Head Office to South Africa and Sub-Saharan Africa) Durban, Cape Town, Bloemfontein and Pretoria
Memberships: Pharmaceutical Industry Association of South Africa (PIASA) and International Federation for Pharmaceutical Manufacturers and Associations (IFPMA)
Strategic partnerships: NGO’s such as CANSA and Breast Health Foundation, Foundation for Professional Development and African Medical and Research Foundation (AMREF)

Activity: Manufactures and markets prescription medicines
Disease areas: Cancer, neuroscience, cardiovascular, respiratory, gastrointestinal, inflammation, infection and diabetes
R&D: Invests over $4-billion in R&D each year. Around 15 700 people work in the R&D organisation and it has 14 major R&D centres in eight countries, including Sweden, the US and the UK. Astra Pharmaceuticals, a generic arm of AstraZeneca Pharmaceuticals, provides novel R&D researched compounds.
Listings: Positioned in the top 8% in the sector in the Dow Jones World and STOXX (European) Sustainability Indices
Awards: AstraZeneca has been rated No.1, eight years in a row in the Pharmaceutical Industry in Managed Health Care in SA, both with Funders and Providers

Financial year-end: December
Holding company: AstraZeneca Pharmaceuticals
Bank: HSBC
Accountants: KPMG
Sales: In 2010 worldwide sales totalled over
$33-billion (including 10 medicines with sales of over $1-billion each)
Market share: In 2011 AstraZeneca contributed 4.2% to the total market of the total pharmaceutical industry in South Africa

CSI: Project Phakamisa, an initiative where diagnosed breast cancer patients are guided and supported in the public system
Programme: Phakamisa – Breast Cancer and Kids Haven


1. Invests over $4-billion in R&D each year
2. Active in over 100 countries with a growing presence in emerging markets including China, Brazil, Mexico and Russia.

AstraZeneca Pharmaceuticals (Pty) Ltd

| |
About The Author